Pembrolizumab plus chemotherapy for cervical cancer

Enfortumab vedotin plus pembrolizumab shows significant survival advantage over previous treatment options, particularly for those ineligible for cisplatin-based therapy. This combination is the first to receive a major added benefit label in this therapeutic indication.

A recent study published in The BMJ suggests that actively monitoring abnormal cells on the cervix rather than removing them immediately may be associated with a higher long-term risk of cervical cancer. Women who underwent active surveillance had a nearly fourfold higher risk of cervical cancer after 20 years compared to those who rec...

A phase III clinical trial found that adding pembrolizumab before and after surgery improved responses and survival in patients with previously untreated, locally advanced head and neck squamous cell carcinoma. Patients treated with pembrolizumab were at least 27% less likely to have experienced recurrence.

Two new Cochrane reviews show that HPV vaccines are effective in preventing cervical cancer and pre-cancerous changes, especially when given to young people before they are exposed to the virus. Girls vaccinated before the age of 16 were found to be 80% less likely to develop cervical cancer.

A phase 3 study found that combining belzutifan with pembrolizumab after surgery significantly improved disease-free survival for high-risk kidney cancer patients. The regimen reduced recurrence by 28% and kept 81% of participants cancer-free.

A new clinical trial found that the addition of immunotherapy drug pembrolizumab to standard treatment improved disease-free survival rates for patients with stage 3 soft tissue sarcoma. The study showed that pembrolizumab reduced recurrence or death for patients by 15 percentage points compared to standard treatment.